Henry Ford Health System

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Henry Ford Health System sits in the top decile of US sponsors by registered trial count (#140 of 15,742 sponsors by registered trial count).

234 total trials 43 currently recruiting 148 completed top decile by trial count

Henry Ford Health System: 234 sponsored US clinical trials, 43 recruiting.

Henry Ford Health System sponsors 234 registered US clinical trials on ClinicalTrials.gov, 43 of them currently recruiting, and 148 completed. 35 of these trials are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Insomnia, with 5 trials.

Top-decile sponsor footprint

Henry Ford Health System ranks in the top decile of sponsors by registered trial count (#140 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 53/100

148 of 173 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

234 total, page 4 of 5

TERMINATED Phase 4

Suvorexant in Insomnia Co-morbid With Fibromyalgia

NCT02684136

COMPLETED

Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX

NCT02609425

COMPLETED Phase 4

Safety and Efficacy of Chronic Hypnotic Use 2

NCT02456532

COMPLETED Phase 1

Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer

NCT02555397

COMPLETED NA

Teen Asthma Control Encouraging a Healthier Lifestyle

NCT02575326

TERMINATED NA

Effect of Combination Non Steroidal Antiinflammatory Drugs and Narrowband UVB Treatment in Non-Photoadapters

NCT05256147

COMPLETED NA

The Effects of Visible Light on the Skin After Administration of Oral Polypodium Leucotomos

NCT02904798

COMPLETED

Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy

NCT02496260

TERMINATED

Change in Exercise Capacity as Measured by Peak Oxygen Uptake After CTO PCI

NCT02499666

COMPLETED NA

Coronal Mode Ultrasound Guided Hemodialysis Cannulation: Comparison With Standard Cannulation Technique

NCT02814721

COMPLETED NA

Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Dioxide Laser Versus Surgical Deroofing

NCT02163746

COMPLETED Phase 3

Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)

NCT02339974

COMPLETED Phase 3

Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery

NCT02352103

COMPLETED

Physical Therapy and Occupational Therapy After Transcatheter Aortic Valve Replacement

NCT03117296

COMPLETED

Current Scope of Practice of Today's Hepatopancreatobiliary Surgeons: A Survey of AHPBA Members

NCT05075733

COMPLETED Phase 4

Liposomal Bupivacaine in Total Shoulder Arthroplasty

NCT02570022

COMPLETED

Immuno-regulatory Profiling of T Cells in GVHD Treated With Extracorporeal Photopheresis

NCT03851601

COMPLETED NA

Transatrial Pericardial Separation to Enhance Safety of Subxiphoid Pericardial Access for Left Atrial Appendage Ligation

NCT06584370

COMPLETED

Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy

NCT02155595

COMPLETED NA

Encouraging Young Adults to Make Effective Nutrition Choices

NCT01979809

COMPLETED

Hemodynamic Effects on Cerebral Autoregulation in Acute Stroke

NCT02056821

COMPLETED Phase 2

Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

NCT02243358

TERMINATED Phase 4

Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit

NCT02025855

COMPLETED NA

Comparison of Scar Results and Time for Closures of Scalp Defects Via Pulley Sutures or Layered Repairs

NCT02744950

COMPLETED

Comparison of Traditional Superficial Cutaneous Sutures Versus Steri-Strip Coaptive Film in Layered Dermatologic Closures

NCT01938586

COMPLETED

Cardiology-Emergency Medicine Cardiac Biomarker Research Initiative

NCT01984853

COMPLETED NA

Web-Based and Tailored Asthma Management Intervention (Puff City) in Teens With Asthma Attending Urban Clinics

NCT01757002

COMPLETED Phase 4

NB-UVB and PUVA Vitiligo Study

NCT01732965

COMPLETED NA

An Investigation Into the Efficacy of Provodine Topical Cream as Compared to 10% Benzoyl Peroxide Wash for the Treatment of Hidradenitis Suppurativa.

NCT01818167

COMPLETED Phase 1

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

NCT01683955

COMPLETED NA

Feasibility of an ED Initiated Online Asthma Management Program for Urban Teens

NCT01695031

COMPLETED

Pilot Evaluation of the JHI Platform

NCT01648673

TERMINATED

Female Acl Prevention Study Where we Look at Landing Techniques Pre/Post Nine Week Strenghtening Program

NCT01729312

TERMINATED Phase 4

Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

NCT01734694

COMPLETED

Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B

NCT01429155

COMPLETED NA

Utility of Interface Pressure Mapping

NCT01439581

COMPLETED NA

Higher Intensity Interval Training in Cardiac Rehabilitation

NCT01606696

COMPLETED Phase 2

Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty

NCT01370460

COMPLETED NA

Cardiac Rehabilitation in Patients With Continuous Flow Left Ventricular Assist Devices:Rehab VAD Trial

NCT01584895

COMPLETED Phase 4

Post-Exposure Prophylaxis in Health Care Workers

NCT01234116

COMPLETED NA

Readiness for Behavior Change After a Heart Attack

NCT01596036

COMPLETED

Association Between Hepatitis C Infection and Renal Cell Carcinoma

NCT01405183

COMPLETED Phase 3

Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy

NCT05718466

COMPLETED NA

Vaginal Cuff Closure in Robotic Hysterectomy

NCT02696239

COMPLETED

PREMIUM Registry: PRognostic HEModynamIc Profiling in the AcUtely Ill EMergency Department Patient

NCT01208077

COMPLETED NA

Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa

NCT01063270

COMPLETED NA

Case-control Study on Matrix Metalloproteinase Levels in Tissue in Patients With Keloid Scar

NCT01125137

COMPLETED NA

Pre-Discharge Bundle for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease to Reduce Readmissions

NCT02135744

COMPLETED NA

Regenerative Tissue Matrix for Breast Reconstruction

NCT01027637

COMPLETED

Effects of Botulinum Toxin in Cervical Dystonia

NCT01056861

← Previous Page 4 of 5 Next →

Phase Distribution

PhaseTrial count
Phase 1 15
Phase 2 23
Phase 3 9
Phase 4 26

What is open in the Henry Ford Health System pipeline

43 recruiting of 234 indexed (18% open); 148 completed (63%).

Phase mix: 35 late (III/IV) vs 38 early (I/II) (balanced across stages).

Top condition: Insomnia (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Henry Ford Health System: open-pipeline peers nationwide

Peers matched on 234 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Henry Ford Health System sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 10%12%14%16%18%20% Total trials Recruiting share Henry Ford Health SystemDaiichi SankyoLoma Linda UniversityBrown UniversityUniversity Hospitals Cleveland Medical CenterNew York Institute of TechnologyUniversity of Maryland, BaltimoreAbramson Cancer Center at Penn MedicineUniversity of California, San Diego
Henry Ford Health System sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Henry Ford Health System sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 234 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Henry Ford Health System page

234 registered trials is a research-attention snapshot, not an endorsement of Henry Ford Health System or any single study.

  • 43 of Henry Ford Health System's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Insomnia is the condition Henry Ford Health System studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Insomnia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Henry Ford Health System pipeline card: 234 registered trials from official public datasets.Report a data error.